# US 2006/0153867 A1 · Pharmaceutical formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153867 A1
- Document ID: US20060153867A1
- Status: Published application
- Kind: A1
- Application number: 11/240,962
- Filed: 2005-09-30
- Published: 2006-07-13
- Earliest claimed: 2004-09-30
- Assignees: KAI Pharmaceuticals, Inc.
- Inventors: Mike Li
- Web page: https://patentgrep.com/patent/US20060153867A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.

## Claims

### Claim 1

A pharmaceutical formulation, comprising:
a protein kinase C modulatory peptide chemically coupled to a transport peptide; and
a sugar, wherein mannitol and the peptide/transporter conjugate are present in a ratio from about 100:1 to about 1:1.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the sugar is selected from the group consisting of fructose, lactose, D-mannose and mannitol.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the ratio is from about 80:1 to about 8:1.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the ratio is from about 80:1 to about 5:1.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the transport peptide is poly-arginine containing peptide.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the transport peptide is a HIV-tat peptide.

### Claim 7 (depends on 1)

The formulation of claim 1, wherein the formulation is lyophilized.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the modulatory peptide is SEQ ID NO: 2-162, or 163.

### Claim 9 (depends on 8)

The formulation of claim 8, wherein the modulatory peptide is SEQ ID NO:33.

### Claim 10 (depends on 9)

The formulation of claim 9, wherein the ratio of the sugar to the modulatory peptide is about 5:1.

### Claim 11 (depends on 1)

The formulation of claim 1, wherein the formulation is suitable for a parenteral route of administration.

### Claim 12 (depends on 11)

The formulation of claim 11, wherein the parenteral route of administration is intracoronary administration.
